Trilok Parekh
About
Trilok Parekh is a scholar working on Pulmonary and Respiratory Medicine, Reproductive Medicine and Oncology.
According to data from OpenAlex, Trilok Parekh has authored 64 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 21 papers in Reproductive Medicine and 20 papers in Oncology. Recurrent topics in Trilok Parekh's work include Ovarian cancer diagnosis and treatment (20 papers), Sarcoma Diagnosis and Treatment (18 papers) and Multiple Myeloma Research and Treatments (13 papers). Trilok Parekh is often cited by papers focused on Ovarian cancer diagnosis and treatment (20 papers), Sarcoma Diagnosis and Treatment (18 papers) and Multiple Myeloma Research and Treatments (13 papers). Trilok Parekh collaborates with scholars based in United States, Spain and Belgium. Trilok Parekh's co-authors include Leslie I. Gold, Roland E. Knoblauch, Youn Choi Park, Andrés Poveda, Alexander I. Spira, George D. Demetri, Margaret von Mehren, Bradley J. Monk, Robert G. Maki and Shreyaskumar Patel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.
In The Last Decade
Trilok Parekh
61 papers receiving 2.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Trilok Parekh United States | 24 | 1.3k | 908 | 875 | 489 | 478 | 64 | 2.6k | ||
| Thomas A. Puchalski United States | 24 | 1.5k 1.2× | 834 0.9× | 905 1.0× | 91 0.2× | 362 0.8× | 51 | 2.8k | ||
| Aristotle Bamias Greece | 28 | 1.9k 1.5× | 792 0.9× | 785 0.9× | 237 0.5× | 171 0.4× | 88 | 3.3k | ||
| D. Fennelly Ireland | 25 | 1.8k 1.4× | 564 0.6× | 417 0.5× | 265 0.5× | 74 0.2× | 85 | 2.6k | ||
| Gerasimos Aravantinos Greece | 36 | 2.3k 1.8× | 1.2k 1.3× | 975 1.1× | 833 1.7× | 138 0.3× | 205 | 4.5k | ||
| Deolinda Pereira Portugal | 26 | 1.3k 1.0× | 323 0.4× | 937 1.1× | 1.3k 2.6× | 59 0.1× | 86 | 2.8k | ||
| Holger W. Hirte Canada | 20 | 978 0.8× | 430 0.5× | 763 0.9× | 433 0.9× | 78 0.2× | 46 | 2.0k | ||
| J H Edmonson United States | 23 | 1.0k 0.8× | 753 0.8× | 334 0.4× | 313 0.6× | 51 0.1× | 45 | 1.8k | ||
| Nicholas E. Papadopoulos United States | 28 | 1.4k 1.1× | 706 0.8× | 870 1.0× | 85 0.2× | 135 0.3× | 82 | 2.4k | ||
| Yusri Elsayed United States | 22 | 1.1k 0.9× | 606 0.7× | 1.1k 1.2× | 39 0.1× | 414 0.9× | 51 | 2.4k | ||
| Edgar Petru Austria | 33 | 1.5k 1.2× | 898 1.0× | 691 0.8× | 1.5k 3.0× | 111 0.2× | 222 | 3.9k |
Countries citing papers authored by Trilok Parekh
Since
Specialization
Citations
This map shows the geographic impact of Trilok Parekh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trilok Parekh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trilok Parekh more than expected).
Fields of papers citing papers by Trilok Parekh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Trilok Parekh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trilok Parekh. The network helps show where Trilok Parekh may publish in the future.
Co-authorship network of co-authors of Trilok Parekh
This figure shows the co-authorship network connecting the top 25 collaborators of Trilok Parekh. A scholar is included among the top collaborators of Trilok Parekh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trilok Parekh. Trilok Parekh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100.
2.
Krishnan, Amrita, Ajay K. Nooka, Ajai Chari, et al.. (2023). Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. Journal of Comparative Effectiveness Research. 12(6). e220186–e220186.
3.
Bahleda, Rastislav, Antoîne Italiano, Cinta Hierro, et al.. (2019). Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical Cancer Research. 25(16). 4888–4897.
4.
Calvo, Emiliano, Analía Azaro, Jordi Rodón, et al.. (2017). Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational New Drugs. 36(3). 476–486.
5.
Hensley, Martee L., Shreyaskumar Patel, Margaret von Mehren, et al.. (2017). Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic Oncology. 146(3). 531–537.
6.
Demetri, George D., Margaret von Mehren, Robin L. Jones, et al.. (2015). Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 34(8). 786–793.
7.
Mehren, Margaret von, Michael A. Bookman, Neal J. Meropol, et al.. (2015). Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 75(5). 1047–1055.
8.
Monk, B.J., Prafull Ghatage, Trilok Parekh, et al.. (2015). Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of Oncology. 26(5). 914–920.
9.
Monk, B.J., Prafull Ghatage, Trilok Parekh, et al.. (2014). Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in subjects with advanced ovarian cancer: Exploratory analysis of phase III OVA-301 study. Gynecologic Oncology. 133. 41–41.
10.
Campo, José María Del, Cristiana Sessa, Carolyn Krasner, et al.. (2013). Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Medical Oncology. 30(1). 435–435.
11.
Monk, Bradley J., Stanley B. Kaye, Andrés Poveda, et al.. (2013). Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial. Gynecologic Oncology. 132(1). 176–180.
12.
Krasner, Carolyn, Andrés Poveda, Thomas J. Herzog, et al.. (2012). Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone. Gynecologic Oncology. 127(1). 161–167.
13.
Poveda, Andrés, Stanley B. Kaye, Robert McCormack, et al.. (2011). Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecologic Oncology. 122(3). 567–572.
14.
Thertulien, Raymond, G. Manikhas, Luc Dirix, et al.. (2011). Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 69(2). 341–350.
15.
Kaye, Stuart, Nicoletta Colombo, B.J. Monk, et al.. (2010). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Annals of Oncology. 22(1). 49–58.
16.
Kurita, Takeshi, Peter Young, Patrı́cia Gama, et al.. (2005). The activation function-1 domain of estrogen receptor α in uterine stromal cells is required for mouse but not human uterine epithelial response to estrogen. Differentiation. 73(6). 313–322.
17.
Khalil, Nasreen, Trilok Parekh, Robert O’Connor, & Leslie I. Gold. (2002). DIFFERENTIAL EXPRESSION OF TRANSFORMING GROWTH FACTOR-β TYPE I AND II RECEPTORS BY PULMONARY CELLS IN BLEOMYCIN-INDUCED LUNG INJURY: CORRELATION WITH REPAIR AND FIBROSIS. Experimental Lung Research. 28(3). 233–250.
18.
Gold, Leslie I. & Trilok Parekh. (1999). Loss of Growth Regulation by Transforming Growth Factor - β (TGF-β) in Human Cancers: Studies on Endometrial Carcinoma. Seminars in Reproductive Medicine. 17(1). 73–92.
19.
McGowan, Stephen E., et al.. (1997). Exogenous and Endogenous Transforming Growth Factors-β Influence Elastin Gene Expression in Cultured Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology. 17(1). 25–35.
20.
Parekh, Trilok, et al.. (1985). Salt mediated changes in some enzymes of carbohydrate metabolism in halotolerantCladosporium sphaerospermum. Journal of Biosciences. 9(3-4). 197–201.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Thomas A. Puchalski Breakdown of academic impact, for papers by Aristotle Bamias Breakdown of academic impact, for papers by D. Fennelly Breakdown of academic impact, for papers by Gerasimos Aravantinos Breakdown of academic impact, for papers by Deolinda Pereira Breakdown of academic impact, for papers by Holger W. Hirte Breakdown of academic impact, for papers by J H Edmonson Breakdown of academic impact, for papers by Nicholas E. Papadopoulos Breakdown of academic impact, for papers by Yusri Elsayed Breakdown of academic impact, for papers by Edgar Petru